1. Home
  2. RGS vs BOLD Comparison

RGS vs BOLD Comparison

Compare RGS & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Regis Corporation

RGS

Regis Corporation

N/A

Current Price

$26.62

Market Cap

72.0M

ML Signal

N/A

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$1.41

Market Cap

36.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
RGS
BOLD
Founded
1922
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
72.0M
36.5M
IPO Year
1994
2024

Fundamental Metrics

Financial Performance
Metric
RGS
BOLD
Price
$26.62
$1.41
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.00
AVG Volume (30 Days)
4.2K
85.7K
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
20.24
32.47
EPS
0.89
N/A
Revenue
$210,134,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$31.20
N/A
Revenue Growth
3.52
N/A
52 Week Low
$18.23
$0.96
52 Week High
$31.50
$1.68

Technical Indicators

Market Signals
Indicator
RGS
BOLD
Relative Strength Index (RSI) 47.77 46.37
Support Level $26.06 $1.40
Resistance Level $28.51 $1.53
Average True Range (ATR) 0.91 0.05
MACD -0.16 -0.01
Stochastic Oscillator 23.50 22.22

Price Performance

Historical Comparison
RGS
BOLD

About RGS Regis Corporation

Regis Corporation owns, franchises, and operates beauty salons in North America and the U.K., serving mainly price-conscious customers. Its salons, located mostly in strip malls, shopping centers, and Walmart stores, offer services like haircutting, styling, shampooing, conditioning, and hair coloring, along with hair care and beauty products. The company's primary brands include Supercuts, SmartStyle, and Cost Cutters. Regis generates the majority of its revenue from these mass-market locations and reports operations in two segments: franchise and company-owned, with services making up about 94% of company-owned salon sales.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: